tricuspid

Abbreviated Antiaggregant Treatment in High Bleeding Risk Patients from the MASTER-DAPT (15-Month Followup)

Benefits of abbreviated antiaggregant treatment in high bleeding risk patients.&nbsp; Dual antiplatelet therapy (DAPT), established by different guidelines, reduces the risk of ischemic events at the expense of increased bleeding. This habitual APT strategy cannot be applied to patients at high risk of bleeding, which is why this populations are treated with shorter DAPT schemes<a href="https://solaci.org/en/2023/05/15/abbreviated-antiaggregant-treatment-in-high-bleeding-risk-patients-from-the-master-dapt-15-month-followup/" title="Read more" >...</a>

Resultados alentadores de los balones cubiertos de Biolimus para el tratamiento de vasos pequeños

PICCOLETO-II: Drug-Coated Balloons in Small Vessels

Use of drug-coated balloons vs. drug-eluting stents in small caliber vessels. The constant advancements in coronary device technology have significantly reduced complication rates (such as that of restenosis). However, there are gaps where a high number of undesirable events prevail, such as small vessel disease (SVD), for which, in previous studies up, the rate of<a href="https://solaci.org/en/2023/04/28/piccoleto-ii-drug-coated-balloons-in-small-vessels/" title="Read more" >...</a>

Sobrevida en pacientes con insuficiencia tricuspídea según variables clínicas y ecocardiográficas (Clusters)

High Implantation of Self-Expanding Valves in the Aortic Position or Cusp Overlapping: Should It Be the New &#8220;Gold Standard&#8221;?

Transcatheter aortic valve replacement (TAVR) has been proving its benefit in different scenarios for two decades now. However, in the field of self-expanding valves, one challenge has always been its high rate of pacemaker implantation compared with balloon-expandable devices and valvular replacement surgery. For this reason, the high implantation or Cusp Overlapping strategy was developed.<a href="https://solaci.org/en/2023/04/20/high-implantation-of-self-expanding-valves-in-the-aortic-position-or-cusp-overlapping-should-it-be-the-new-gold-standard/" title="Read more" >...</a>

The most read scientific articles in interventional cardiology in March on our website

Below, we share March&#8217;s most read scientific abstracts in interventional cardiology at solaci.org. ACC 2023 | YELLOW III Study. Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease Dr. Kini presented the results of the YELLOW III Study where she analyzed the effect of evolocumab on coronary plaque in patients with stable<a href="https://solaci.org/en/2023/04/13/the-most-read-scientific-articles-in-interventional-cardiology-in-march-on-our-website/" title="Read more" >...</a>

Costo efectividad de la reparación endovascular y quirúrgica en aneurismas complejos

MitraScore: What Does the Final Result of Edge-to-Edge Treatment of Mitral Regurgitation Provide?

Edge-to-edge treatment has proven to be a safe and effective technique in follow-up, decreasing mortality and hospitalizations for heart failure when a good result is achieved. The MitraScore was developed to assess the outcome at the end of the procedure. In that sense, results &lt;3 represent mild mitral regurgitation, which would be related to lower<a href="https://solaci.org/en/2023/03/31/mitrascore-what-does-the-final-result-of-edge-to-edge-treatment-of-mitral-regurgitation-provide/" title="Read more" >...</a>

Endocarditis infecciosa post TAVI

Amyloidosis and TAVR: Does this Disease Have an Impact?

Amyloidosis is a systemic disease that affects different organs and impairs their function. Recent studies with magnetic resonance imaging (MRI) have shown that between 13% and 16% of patients who undergo transcatheter aortic valve replacement (TAVR) have amyloidosis.&nbsp; A review of four studies showed that mortality at 20 months was twice as high when amyloidosis<a href="https://solaci.org/en/2023/03/28/amyloidosis-and-tavr-does-this-disease-have-an-impact/" title="Read more" >...</a>

Debemos tener en cuenta a la isquemia crítica de MM II en el TAVI

When Is It Best to Fracture a Bioprosthesis in TAVR?

At present, surgical aortic valve replacement (SAVR) uses bioprostheses. However, when these fail, we are presented with a great challenge, seeing as repeat SAVR involves a higher risk. In this context, valve-in-valve (V-in-V TAVR) has surged as a very attractive alternative.&nbsp; Bioprosthesis fracture (BPF) is a new interesting strategy that has shown lower gradient and<a href="https://solaci.org/en/2023/03/28/when-is-it-best-to-fracture-a-bioprosthesis-in-tavr/" title="Read more" >...</a>

ACC 2023 | YELLOW III Study. Effect of Evolocumab on Coronary Plaque Characteristics in Stable Coronary Artery Disease

Dr. Kini presented the results of the YELLOW III Study where she analyzed the effect of evolocumab on coronary plaque in patients with stable coronary artery disease. The study included 137 patients who underwent coronary angioplasty to the culprit vessel and endovascular imaging (OCT, NIRS/IVUS) to non-obstructive lesions (30%-50%). If their plaque was lipid-rich (defined<a href="https://solaci.org/en/2023/03/08/acc-2023-yellow-iii-study-effect-of-evolocumab-on-coronary-plaque-characteristics-in-stable-coronary-artery-disease/" title="Read more" >...</a>

¿Qué usar para medir funcionalmente una lesión coronaria en el contexto de estenosis aórtica severa?

Secondary Mitral Regurgitation: Stages of Heart Failure and Prognostic Implications after Transcatheter Edge-to-Edge Repair

We are already familiar with the strong impact of secondary mitral valve regurgitation (SMR) in survival and quality of life. &nbsp;Most of these patients present heart failure (HF) with reduced ejection fraction (HFrEF). Stages of heart failure based on extra-mitral cardiac involvement has been shown relevant. There is also extensive research on aortic valve disease<a href="https://solaci.org/en/2023/01/09/secondary-mitral-regurgitation-stages-of-heart-failure-and-prognostic-implications-after-transcatheter-edge-to-edge-repair/" title="Read more" >...</a>

La reparación de la válvula mitral con Mitraclip es segura en pacientes de alto riesgo

Is the PASCAL Device Effective against MitraClip?

Mitral regurgitation (MR) is the most common valvulopathy and full medical treatment at maximal tolerated doses has been shown quite effective to treat it. However, its limited in a group of patients that require valve intervention.&nbsp; At present, the ideal treatment is surgical valve replacement, which is in many cases is not viable because of<a href="https://solaci.org/en/2022/12/30/is-the-pascal-device-effective-against-mitraclip/" title="Read more" >...</a>

Top